Is AVXL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AVXL. It does not provide personalized investment advice.

AVXL (Anavex Life Sciences) Stock Analysis - Financials

Anavex Life Sciences (AVXL) is a publicly traded Healthcare sector company. As of November 3, 2026, AVXL trades at $1.15 with a market cap of $110.31M and a P/E ratio of -2.88. AVXL moved -3.78% today. Year to date, AVXL is -68.91%; over the trailing twelve months it is -85.65%. Its 52-week range spans $1.14 to $13.99. Rallies surfaces AVXL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are AVXL's key financials?

AVXL financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. AVXL recently traded at $1.15. Market cap is $110.31M. P/E ratio is -2.88. Revenue is $4.68M.

AVXL Key Metrics

Key financial metrics for AVXL
Metric	Value
Price	$1.15
Market Cap	$110.31M
P/E Ratio	-2.88
EPS	$-0.54
Dividend Yield	0.00%
52-Week High	$13.99
52-Week Low	$1.14
Volume	1.03M
Avg Volume	0
Revenue (TTM)	$4.68M
Net Income	$-46.38M
Gross Margin	0.00%

AVXL Analyst Consensus

AVXL analyst coverage data. Average price target: $0.00.

Common questions about AVXL

What are AVXL's key financials?: AVXL financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. AVXL recently traded at $1.15. Market cap is $110.31M. P/E ratio is -2.88. Revenue is $4.68M.
Is AVXL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AVXL. It does not provide personalized investment advice.